Table 3.
Correlation between CAPRIN2 and CRC patients’ clinical features
| Characteristics | n (39) | CAPRIN2 expression (%) |
P value | |
|---|---|---|---|---|
| Low (n = 20) | High (n = 19) | |||
| Gender | ||||
| Male | 22 (56.4) | 13 (65.0) | 9 (47.4) | 0.267 |
| Female | 17(43.6) | 7 (35.0) | 10 (52.6) | |
| Age | ||||
| <60 | 24 (61.5) | 11 (55.0) | 13 (68.4) | 0.389 |
| ≥60 | 15 (38.5) | 9 (45.0) | 6 (31.6) | |
| Tumor Size | ||||
| <5 cm | 18 (46.2) | 12(60.0) | 6 (31.6) | 0.075 |
| ≥5 cm | 21 (53.8) | 8 (40.0) | 13 (68.4) | |
| TNM stage | ||||
| I–II | 15 (38.5) | 12 (60.0) | 3 (15.8) | 0.005* |
| III–IV | 24 (61.5) | 8 (40.0) | 16 (84.2) | |
| Differentiation | ||||
| Low | 15 (38.5) | 3 (15.0) | 12 (63.2) | 0.008* |
| Moderate | 13 (33.3) | 9 (45.0) | 4 (21.0) | |
| High | 11 (28.2) | 8 (40.0) | 3 (15.8) | |
| Distant metastasis | ||||
| M0 | 14 (35.9) | 11 (55.0) | 3 (15.8) | 0.011* |
| M1 | 25 (64.1) | 9 (45.0) | 16 (84.2) | |
*P < 0.05.